The TGC-Fast Trial, featured in the New England Journal of Medicine in 2023, was a multicenter, randomized, controlled trial that aimed to assess the benefits of tight glucose control without early parenteral nutrition in the intensive care unit (ICU). The … Read More
insulin
SURPASS-6 Trial: Tirzepatide in T2DM
The SURPASS-6 trial, featured in JAMA in October 2023, represents a significant advancement in the treatment of type 2 diabetes. This randomized, phase 3, open-label trial was designed to evaluate the effects of once-weekly subcutaneous (SC) tirzepatide versus thrice-daily prandial … Read More
DIGAMI 2 Trial: Insulin-Based Glucose Control in Type 2 Diabetic Patients Following MI
DIGAMI 2 Trial Summary Introduction:The DIGAMI 2 trial aimed to evaluate the effect of insulin-based glucose control in type 2 diabetic patients following myocardial infarction compared to conventional management at similar levels of glucose control. The study investigated three treatment … Read More
ACCORD Trial: Intensive Glucose Lowering in DM2
ACCORD: Effects of Intensive Glucose Lowering in Type 2 Diabetes Multicenter, double-blinded, two-by-two factorial, randomized controlled trial Objective: To assess if intensive glycemic control targeting a HbA1c <6% versus standard glycemic control targeting a HbA1c 7-7.9% reduce the risk of … Read More